Literature DB >> 24047898

Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry.

Mikyung Kim1, Likai Song, James Moon, Zhen-Yu J Sun, Anna Bershteyn, Melissa Hanson, Derek Cain, Selasie Goka, Garnett Kelsoe, Gerhard Wagner, Darrell Irvine, Ellis L Reinherz.   

Abstract

Structural characterization of epitope-paratope pairs has contributed to the understanding of antigenicity. By contrast, few structural studies relate to immunogenicity, the process of antigen-induced immune responses in vivo. Using a lipid-arrayed membrane-proximal external region (MPER) of HIV-1 glycoprotein 41 as a model antigen, we investigated the influence of physicochemical properties on immunogenicity in relation to structural modifications of MPER/liposome vaccines. Anchoring the MPER to the membrane via an alkyl tail or transmembrane domain retained the MPER on liposomes in vivo, while preserving MPER secondary structure. However, structural modifications that affected MPER membrane orientation and antigenic residue accessibility strongly impacted induced antibody responses. The solvent-exposed MPER tryptophan residue (Trp-680) was immunodominant, focusing immune responses, despite sequence variability elsewhere. Nonetheless, immunogenicity could be readily manipulated using site-directed mutagenesis or structural constraints to modulate amino acid surface display. These studies provide fundamental insights for immunogen design aimed at targeting B cell antibody responses.

Entities:  

Keywords:  Antibodies; HIV-1; Immunodominance; Immunogenicity; Infectious Diseases; Protein Structure; Vaccine Development

Mesh:

Substances:

Year:  2013        PMID: 24047898      PMCID: PMC3814781          DOI: 10.1074/jbc.M113.494609

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Refocusing of B-cell responses following a single amino acid substitution in an antigen.

Authors:  M D Chiesa; P M Martensen; C Simmons; N Porakishvili; J Justesen; G Dougan; I M Roitt; P J Delves; T Lund
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

2.  Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA.

Authors:  Torsten Herrmann; Peter Güntert; Kurt Wüthrich
Journal:  J Mol Biol       Date:  2002-05-24       Impact factor: 5.469

3.  Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.

Authors:  Juergen Zlatkovic; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

4.  Computational characterization of B-cell epitopes.

Authors:  Nimrod D Rubinstein; Itay Mayrose; Dan Halperin; Daniel Yekutieli; Jonathan M Gershoni; Tal Pupko
Journal:  Mol Immunol       Date:  2007-11-26       Impact factor: 4.407

5.  Stepwise intraclonal maturation of antibody affinity through somatic hypermutation.

Authors:  C Kocks; K Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

6.  Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

Authors:  Florian Klein; Ron Diskin; Johannes F Scheid; Christian Gaebler; Hugo Mouquet; Ivelin S Georgiev; Marie Pancera; Tongqing Zhou; Reha-Baris Incesu; Brooks Zhongzheng Fu; Priyanthi N P Gnanapragasam; Thiago Y Oliveira; Michael S Seaman; Peter D Kwong; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

Review 7.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

Authors:  Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

8.  An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies.

Authors:  Xiaocong Yu; Patricia A McGraw; Frances S House; James E Crowe
Journal:  J Immunol Methods       Date:  2008-05-05       Impact factor: 2.303

9.  Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41.

Authors:  Douglas S Watson; Francis C Szoka
Journal:  Vaccine       Date:  2009-06-09       Impact factor: 3.641

10.  Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41.

Authors:  S Moses Dennison; Laura L Sutherland; Frederick H Jaeger; Kara M Anasti; Robert Parks; Shelley Stewart; Cindy Bowman; Shi-Mao Xia; Ruijun Zhang; Xiaoying Shen; Richard M Scearce; Gilad Ofek; Yongping Yang; Peter D Kwong; Sampa Santra; Hua-Xin Liao; Georgia Tomaras; Norman L Letvin; Bing Chen; S Munir Alam; Barton F Haynes
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

View more
  24 in total

1.  Thermodynamic analysis of the binding of 2F5 (Fab and immunoglobulin G forms) to its gp41 epitope reveals a strong influence of the immunoglobulin Fc region on affinity.

Authors:  Sara Crespillo; Salvador Casares; Pedro L Mateo; Francisco Conejero-Lara
Journal:  J Biol Chem       Date:  2013-12-03       Impact factor: 5.157

2.  Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.

Authors:  Melissa C Hanson; Monica P Crespo; Wuhbet Abraham; Kelly D Moynihan; Gregory L Szeto; Stephanie H Chen; Mariane B Melo; Stefanie Mueller; Darrell J Irvine
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

3.  The membrane proximal external regions of gp41 from HIV-1 strains HXB2 and JRFL have different sensitivities to alanine mutation.

Authors:  Hyun Ah Yi; Barbara Diaz-Rohrer; Priyanka Saminathan; Amy Jacobs
Journal:  Biochemistry       Date:  2015-02-19       Impact factor: 3.162

4.  The Atomic Structure of the HIV-1 gp41 Transmembrane Domain and Its Connection to the Immunogenic Membrane-proximal External Region.

Authors:  Beatriz Apellániz; Edurne Rujas; Soraya Serrano; Koldo Morante; Kouhei Tsumoto; Jose M M Caaveiro; M Ángeles Jiménez; José L Nieva
Journal:  J Biol Chem       Date:  2015-03-18       Impact factor: 5.157

5.  Topological analysis of the gp41 MPER on lipid bilayers relevant to the metastable HIV-1 envelope prefusion state.

Authors:  Yi Wang; Pavanjeet Kaur; Zhen-Yu J Sun; Mostafa A Elbahnasawy; Zahra Hayati; Zhi-Song Qiao; Nhat N Bui; Camila Chile; Mahmoud L Nasr; Gerhard Wagner; Jia-Huai Wang; Likai Song; Ellis L Reinherz; Mikyung Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-17       Impact factor: 11.205

Review 6.  Vaccine nanoparticles for protection against HIV infection.

Authors:  Marisa E Aikins; Joseph Bazzill; James J Moon
Journal:  Nanomedicine (Lond)       Date:  2017-02-21       Impact factor: 5.307

Review 7.  Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.

Authors:  Laurent Verkoczy; Marilyn Diaz
Journal:  Curr Opin HIV AIDS       Date:  2014-05       Impact factor: 4.283

8.  Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides.

Authors:  Melissa C Hanson; Wuhbet Abraham; Monica P Crespo; Stephanie H Chen; Haipeng Liu; Greg Lee Szeto; Mikyung Kim; Ellis L Reinherz; Darrell J Irvine
Journal:  Vaccine       Date:  2015-01-02       Impact factor: 3.641

Review 9.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

10.  Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits.

Authors:  Vincent J Venditto; Lindsay Wieczorek; Sebastian Molnar; Fernando Teque; Gary Landucci; Douglas S Watson; Donald Forthal; Victoria R Polonis; Jay A Levy; Francis C Szoka
Journal:  Clin Vaccine Immunol       Date:  2014-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.